Target intelligence / Profile preview

E3 ubiquitin-protein ligase SMURF1 (SMURF1)

Target
SMURF1
Molecular classification
Enzyme, E3 ubiquitin-protein ligase, HECT-type E3 ubiquitin ligase, Nedd4 family
01

Overview

E3 ubiquitin-protein ligase SMURF1 (SMAD-specific E3 ubiquitin protein ligase 1) is a HECT-type E3 ubiquitin ligase belonging to the Nedd4 family. It plays a critical role in regulating cell growth, migration, polarity, and autophagy by targeting specific substrate proteins—such as SMAD1, SMAD5, and bone morphogenetic protein receptor type 2 (BMPR2)—for polyubiquitination and subsequent proteasomal degradation. Dysregulation of SMURF1 is heavily implicated in the pathogenesis of pulmonary arterial hypertension (PAH), where its overexpression leads to the degradation of BMPR2 and impaired BMP signaling, driving pathological vascular remodeling. Additionally, SMURF1 is associated with idiopathic pulmonary fibrosis (IPF), osteoporosis, and various cancers, where it often acts as an oncogene. Therapeutic strategies targeting SMURF1 focus on small-molecule inhibitors, such as the clinical candidate LTP001, which aim to stabilize BMPR2 and restore homeostatic BMP signaling to reverse vascular remodeling.

Other names
SMAD-specific E3 ubiquitin protein ligase 1Smad ubiquitination regulatory factor 1Smad ubiquitylation regulatory factor 1SMURF-1
02

Mechanism of action

Inhibition of SMURF1 E3 ubiquitin ligase activity, preventing the ubiquitination and subsequent proteasomal degradation of target proteins such as BMPR2, SMAD1, and SMAD5, thereby restoring or enhancing BMP/TGF-beta signaling pathways.

03

Biological functions

UbiquitinationProteasomal degradationTGF-beta signaling pathway regulationBMP signaling pathway regulationCell growthCell migrationCell polarityAutophagyOsteogenesisInnate immune response regulation
04

Disease associations

Pulmonary arterial hypertensionIdiopathic pulmonary fibrosisCancerOsteoporosisInflammatory diseaseNeurodegenerative disease
05

Safety considerations

Potential for off-target effects due to homology with SMURF2Impaired bone remodeling or osteogenesisAlterations in glucose homeostasis (hypoglycemia risk based on insulin receptor degradation pathways)Impaired antiviral or innate immune responses due to role in MAVS/MyD88 regulationRisk of promoting fibrosis or tissue remodeling in non-target organs
06

Interacting drugs

2 more in the full profile.

07

Biomarkers

SMURF1 expression levelsBMPR2 expression levelsSMAD1/5 phosphorylationPulmonary vascular resistance (PVR)Six-minute walk distance (6MWT)

Beyond the preview

Go deeper on E3 ubiquitin-protein ligase SMURF1 (SMURF1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on E3 ubiquitin-protein ligase SMURF1 (SMURF1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call